ScholarLens Back to search
2006•Journal of Pharmacology and Experimental TherapeuticsRequires access

Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level

Kenji Katsuno, Yoshikazu Fujimori, Yukiko Takemura, Masahiro Hiratochi, Fumiaki Itoh, Yoshimitsu Komatsu, Hideki Fujikura, Masayuki Isaji

Open publisher page 267 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 267 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Renal glucose reabsorption, Phlorizin, Chemistry, Endocrinology, Cotransporter, Internal medicine, Phloretin, Glucose transporter

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level — Research Paper | ScholarLens